News Release: Healthcare Trust of America, Inc. Announces Leadership Transition

August 3, 2021

Director Peter N. Foss Named Interim President and CEO

Lead Independent Director W. Bradley Blair, II Elected as Chairman of the Board

Scott D. Peters Resigns as Chairman of the Board, President and CEO

NEWS PROVIDED BY Healthcare Trust of America, Inc. 

Aug 03, 2021, 16:15 ET

SCOTTSDALE, ARIZONA, August 3, 2021 – Healthcare Trust of America, Inc. (the “Company”) (NYSE: HTA) today announced that its Board of Directors has named one of its independent directors, Peter N. Foss, as Interim President and Chief Executive Officer, effective August 2, 2021. Scott D. Peters resigned effective August 2, 2021 as a director, Chairman of the Board, President and Chief Executive Officer of the Company. Effective August 2, 2021, the Lead Independent Director of the Board, W. Bradley Blair, II, was elected to be Chairman of the Board. Mr. Foss has stepped down as a member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board, but has remained a member of the Board’s Investment Committee. Warren D. Fix, an independent director currently serving on the Board, has replaced Mr. Foss as Chairman of the Board’s Compensation Committee.

“Peter has been on HTA’s board since April 2015 and is well-versed in the Company’s strategy and has deep experience in the healthcare industry,” Blair said. “He has been involved in numerous Board committees and he, along with the strong management team, are well positioned to guide HTA through this transition.”

About Peter N. Foss

Peter Foss has served as an independent director of the Company since April 2015. He provides the Company strong leadership skills through significant experience in customer relationships and stakeholder and employee engagement. He is a 35 year veteran of General Electric Company (“GE”) where he was President of GE’s Olympic Sponsorship and Corporate Accounts from 2003 until his retirement in February 2013. In addition, Mr. Foss directed the Corporate Sales Program at GE. Mr. Foss was rehired by GE in November 2013 to serve as the leader of the GE/NFL Brain Research Program. Prior to his most recent positions, he served for six years as the President of GE Polymerland, a commercial organization representing GE Plastics in the global marketplace. Prior to GE Polymerland, Mr. Foss served in various commercial roles with GE, including introducing LEXAN® film in the 1970s, and was the Market Development Manager on the ULTEM® introduction team in 1982. He has also served as the Regional General Manager for four of the GE Plastics regions, including leading the GE Plastics effort in Mexico in the mid-1990s. Mr. Foss serves on the board of Savista (formerly nThrive), a private company. Mr. Foss previously served on the board of directors of First Horizon National Corporation, Capital Bank Corp., Green Bankshares and TIB Financial Corp.

About W. Bradley Blair, II

Mr. Blair was appointed as the lead independent director of the Company’s Board of Directors in December 2014 and has served as an independent director of the Company since September 2006. Mr. Blair served as the Chief Executive Officer, President and Chairman of the board of directors of Golf Trust of America, Inc. (now known as Pernix Therapeutics Holdings, Inc.) from the time of its formation as a REIT and initial public offering in 1997 until his resignation and retirement in November 2007. During that term, Mr. Blair managed the acquisition, operation, leasing and disposition of the assets of the portfolio. From 1993 until February 1997, Mr. Blair served as Executive Vice President, Chief Operating Officer and General Counsel for The Legends Group. As an officer of The Legends Group, Mr. Blair was responsible for all aspects of its operations, including acquisitions, development and marketing. From 1978 to 1993, Mr. Blair was the managing partner at Blair Conaway Bograd & Martin, P.A., a law firm specializing in real estate, finance, taxation and acquisitions.

About HTA

Healthcare Trust of America, Inc. (NYSE: HTA) is the largest dedicated owner and operator of medical office buildings in the United States, with assets comprising approximately 25.6 million square feet of GLA, with $7.5 billion invested primarily in medical office buildings as of March 31, 2021. HTA provides real estate infrastructure for the integrated delivery of healthcare services in highly-desirable locations. Investments are targeted to build critical mass in 20 to 25 leading gateway markets that generally have leading university and medical institutions, which translates to superior demographics, high-quality graduates, intellectual talent and job growth. The strategic markets HTA invests in support a strong, long-term demand for quality medical office space. HTA utilizes an integrated asset management platform consisting of on-site leasing, property management, engineering and building services, and development capabilities to create complete, state of the art facilities in each market. We believe this drives efficiencies, strong tenant and health system relationships, and strategic partnerships that result in high levels of tenant retention, rental growth and long-term value creation. Headquartered in Scottsdale, Arizona, HTA has developed a national brand with dedicated relationships at the local level.

Founded in 2006 and listed on the New York Stock Exchange in 2012, HTA has produced attractive returns for its stockholders that have outperformed the US REIT index. More information about HTA can be found on the Company’s Website (www.htareit.com), Facebook, LinkedIn, Instagram and Twitter.

Forward-Looking Language

This press release contains certain forward-looking statements. Forward-looking statements are based on current expectations, plans, estimates, assumptions and beliefs, including expectations, plans, estimates, assumptions and beliefs about HTA, stockholder value and earnings growth.

The forward-looking statements included in this press release are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond HTA’s control. Although HTA believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, HTA’s actual results and performance could differ materially and in adverse ways from those set forth in the forward-looking statements. Factors which could have a material adverse effect on HTA’s operations and future prospects include, but are not limited to:

the Company’s ability to effectively deploy proceeds of offerings of securities;
changes in economic conditions affecting the healthcare property sector, the commercial real estate market and the credit market;
competition for acquisition and development of medical office buildings and other facilities that serve the healthcare industry;
the Company’s ability to acquire or develop real properties, and to successfully operate those properties once acquired or developed;
pandemics and other health concerns, and the measures intended to prevent their spread, including the currently ongoing COVID-19 pandemic;
economic fluctuations in certain states in which the Company’s investments are geographically concentrated;
financial stability and solvency of the Company’s tenants, including the ability and willingness of the Company’s tenants or borrowers to satisfy obligations under their respective contractual arrangements with the Company and the potential inability of the Company to enforce its rights under its leases during the pendency of any pandemic;
the ability and willingness of the Company’s tenants to renew their leases with the Company upon expiration of the leases or the Company’s ability to reposition its properties on the same or better terms in the event of a nonrenewal or in the event the Company exercises its right to replace an existing tenant;
fluctuations in reimbursements from third party payors such as Medicare and Medicaid;
supply and demand for operating properties in the market areas in which the Company operates;
changes in operating expenses of the Company’s properties including, but not limited to, expenditures for property taxes, property and liability insurance premiums, and utility rates;
the Company’s ability and the ability of its tenants to obtain and maintain adequate property, liability and other insurance from reputable, financial stable providers;
restrictive covenants on certain of the Company’s properties subject to ground leases that may restrict or limit the uses of its properties and the types of tenants the Company is able to lease to, and the Company’s ability to attract new tenants;
the impact from damage to the Company’s properties from, or increased operating costs associated with, catastrophic weather and other natural events and the physical effect of climate change;
retention of the Company’s senior management team and its ability to attract and retain qualified key personnel;
legislative and regulatory changes, including changes to laws governing the taxation of real estate investment trusts (“REITs”) and changes to laws governing the healthcare industry;
changes in interest rates, including changes as a result of the phasing out of the London Inter-bank Offered Rate (“LIBOR”) effective June 30, 2023;
the availability of capital and financing;
restrictive covenants in the Company’s credit facilities;
changes in the Company’s credit ratings;
HTA’s ability to remain qualified as a REIT;
changes in accounting principles generally accepted in the United States of America, policies and guidelines applicable to REITs; and
the risk factors set forth in HTA’s most recent Annual Report on Form 10-K and in HTA’s most recent Quarterly Reports on Form 10-Q.
Forward-looking statements speak only as of the date made. Except as otherwise required by the federal securities laws, HTA undertakes no obligation to update any forward-looking statements to reflect the events or circumstances arising after the date as of which they are made. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on the forward-looking statements included in this press release or that may be made elsewhere from time to time by, or on behalf of, HTA.